Pharma BD Deal Intelligence
AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction at $135.11 per share, deepening AbbVie's immunology portfolio. Apogee's lead candidate zumilokibart (APG777) is a subcutaneous, half-life-extended anti-IL-13 monoclonal antibody in development for atopic dermatitis and asthma, with Phase 2 data showing ~two-thirds of treated patients achieving significant skin clearance at 16 weeks on quarterly or twice-yearly dosing. It is the year's second-largest biotech acquisition.